Role of myeloid-derived suppressor cells in tumor immunotherapy.

Abstract:

:Myeloid-derived suppressor cells (MDSCs) are immature myeloid cells that infiltrate human and experimental tumors and strongly inhibit anticancer immune response directly or by inducing regulatory T-lymphocyte activity. Consequently, MDSCs are important actors of cancer-induced immune tolerance and a major obstacle to efficiency of cancer immunotherapy. Several means of preventing MDSCs accumulation or inhibiting their immunosuppressive effect were recently discovered in cancer-bearing hosts, contributing to restoring antitumor immunity and consequently to control of tumor growth. In experimental tumor models, targeting MDSCs can enhance the effects of active or passive immunotherapy. While similar effects have not yet been noted in cancer-bearing patients, recent preclinical findings demonstrating that the selective toxicity of conventional chemotherapies such as gemcitabine and 5-fluorouracil on MDSCs might contribute to their anticancer effect provide impetus to pursue investigations to unravel novel therapeutics that target MDSCs in humans.

journal_name

Immunotherapy

journal_title

Immunotherapy

authors

Martin F,Apetoh L,Ghiringhelli F

doi

10.2217/imt.11.154

subject

Has Abstract

pub_date

2012-01-01 00:00:00

pages

43-57

issue

1

eissn

1750-743X

issn

1750-7448

journal_volume

4

pub_type

杂志文章,评审
  • Nivolumab plus ipilimumab for soft tissue sarcoma: a single institution retrospective review.

    abstract::Aim: To analyze the efficacy of checkpoint inhibitors in soft tissue sarcoma. Materials & methods: We retrospectively reviewed patients with advanced soft tissue sarcoma treated with ipilimumab and nivolumab. All patients who received at least one cycle were included. Results: One patient had a complete response and f...

    journal_title:Immunotherapy

    pub_type: 杂志文章

    doi:10.2217/imt-2020-0155

    authors: Zhou M,Bui N,Bolleddu S,Lohman M,Becker HC,Ganjoo K

    更新日期:2020-12-01 00:00:00

  • Small-molecule protein kinase inhibitors and their effects on the immune system: implications for cancer treatment.

    abstract::Oncogenic signaling pathways have emerged as key targets for the development of small-molecule inhibitors, with several protein kinase inhibitors already in clinical use for cancer patients. In addition to their role in tumorigenesis, many of the molecules and signaling pathways targeted by these inhibitors are also i...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt.10.99

    authors: Ott PA,Adams S

    更新日期:2011-02-01 00:00:00

  • Characterization of monocyte-derived dendritic cells used in immunotherapy for HIV-1-infected individuals.

    abstract:AIMS:A therapeutic vaccine based on monocyte-derived dendritic cells (MDDCs) has been shown to represent a promising strategy for the treatment of cancer and viral infections. Here, we characterized the MDDCs used as an immunogen in a clinical trial for an anti-HIV-1 therapeutic vaccine. PATIENTS & METHODS:Monocytes o...

    journal_title:Immunotherapy

    pub_type: 杂志文章

    doi:10.2217/imt-2017-0165

    authors: da Silva LT,da Silva WC,de Almeida A,da Silva Reis D,Santillo BT,Rigato PO,da Silva Duarte AJ,Oshiro TM

    更新日期:2018-08-01 00:00:00

  • PD-L1 expression and outcome of advanced melanoma patients treated with anti-PD-1/PD-L1 agents: a meta-analysis.

    abstract:AIM:This meta-analysis aims at assessing the correlation of PD-L1 levels and response PD-1/PD-L1 inhibitors in advanced malignant melanoma. METHODS:Eligible studies included those evaluating PD-1/PD-L1 inhibitors in advanced melanoma and correlating the outcomes to PD-L1 levels. RESULTS:After preclusion of ineligible...

    journal_title:Immunotherapy

    pub_type: 杂志文章,meta分析

    doi:10.2217/imt-2016-0025

    authors: Abdel-Rahman O

    更新日期:2016-09-01 00:00:00

  • Reslizumab for pediatric eosinophilic esophagitis.

    abstract::Pediatric eosinophilic esophagitis is an inflammatory condition associated with marked eosinophil accumulation in the mucosal tissues of the esophagus. Eosinophils are major proinflammatory cells thought to make a major contribution to allergic diseases that affect the upper and lower airways, skin and GI tract. IL-5 ...

    journal_title:Immunotherapy

    pub_type: 杂志文章

    doi:10.2217/imt.10.41

    authors: Walsh GM

    更新日期:2010-07-01 00:00:00

  • What is the role of antigen-processing mechanisms in autologous tolerogenic dendritic cell therapy in organ transplantation?

    abstract::Injection of autologous tolerogenic dendritic cells is a promising strategy to diminish the burden of harmful immunosuppression in clinical transplantation. We discuss the immunoregulatory mechanisms triggered by this approach. Tolerogenic dendritic cells have long been associated with decreased antigen-processing cap...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt.11.40

    authors: Hill M,Segovia M,Cuturi MC

    更新日期:2011-04-01 00:00:00

  • Heat-shock proteins as endogenous ligands building a bridge between innate and adaptive immunity.

    abstract::There has been growing evidence that heat-shock protein (HSP) functions as an endogenous immunomodulator for innate and adaptive immune responses. Since HSPs inherently act as chaperones within cells, passive release (e.g., by cell necrosis) and active release (including release by secretion in the form of an exosome)...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt.12.75

    authors: Tamura Y,Torigoe T,Kukita K,Saito K,Okuya K,Kutomi G,Hirata K,Sato N

    更新日期:2012-08-01 00:00:00

  • The split personality of NKT cells in malignancy, autoimmune and allergic disorders.

    abstract::NKT cells are a heterogeneous subset of specialized, self-reactive T cells, with innate and adaptive immune properties, which allow them to bridge innate and adaptive immunity and profoundly influence autoimmune and malignant disease outcomes. NKT cells mediate these activities through their ability to rapidly express...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt.11.117

    authors: Subleski JJ,Jiang Q,Weiss JM,Wiltrout RH

    更新日期:2011-10-01 00:00:00

  • Adoptive therapy for EBV-induced cancers: driving success with post-transplant lymphoproliferative disorder to other EBV-derived tumors.

    abstract::Epstein-Barr virus (EBV) infection is associated with a range of human malignancies of lymphocytic and epithelial cell origin. In addition to viral-mediated and genetic oncogenic events that lead to the establishment of EBV-associated malignancies, defects in the immune control of EBV likely play a significant role in...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt.15.7

    authors: Smith C,Khanna R

    更新日期:2015-01-01 00:00:00

  • Designing two-in-one antibodies.

    abstract::Evaluation of: Bostrom J, Shang-Fan Y, Kan D et al.: Variants of the antibody Herceptin that interact with HER2 and VEGF at the antigen binding site. Science 323, 1610-1614 (2009). The longstanding held notion that one antibody equals one antigen and, hence, one function has been challenged in recent years. Improved t...

    journal_title:Immunotherapy

    pub_type: 评论,杂志文章

    doi:10.2217/imt.09.39

    authors: Valladares IG,Espinoza LR

    更新日期:2009-09-01 00:00:00

  • Pasteurized and nanofiltered, plasma-derived C1 esterase inhibitor concentrate for the treatment of hereditary angioedema.

    abstract::Hereditary angioedema (HAE) is a relatively rare autosomal dominant disorder that is typically characterized by recurrent episodes of edema in various body locations. It is most commonly caused by an inherited deficiency of functionally active C1 esterase inhibitor (C1-INH). Replacement therapy with a human plasma-der...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt.14.33

    authors: Bork K

    更新日期:2014-01-01 00:00:00

  • T-regulatory/T-helper 17: promiscuous signals and fear of commitment.

    abstract::The insight gained recently on the differentiation of naive CD4 T cells challenges the dogma that expression of canonical transcription factors and production of signature cytokines portray a commitment to a specific lineage and a point of no return. For almost two decades now, the belief has been that naive CD4 T cel...

    journal_title:Immunotherapy

    pub_type: 评论,杂志文章

    doi:10.2217/1750743X.1.1.27

    authors: Tartar DM,van Morlan AM,Zaghouani H

    更新日期:2009-01-01 00:00:00

  • Anti-TNF therapeutics for the treatment of sarcoidosis.

    abstract::Sarcoidosis is a systemic disease with an incidence of 1 to 40 per 100 000 persons per year. It predominantly affects people in the age of 20 to 40 years old. Disease course varies from mild self-limiting to chronic debilitating and life-threatening disease. Since the cause of sarcoidosis is unknown, curative therapy ...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt.14.65

    authors: Crommelin HA,Vorselaars AD,van Moorsel CH,Korenromp IH,Deneer VH,Grutters JC

    更新日期:2014-01-01 00:00:00

  • Dendritic cell vaccines targeting survivin in head and neck cancer.

    abstract::Evaluation of: Turksma AW, Bontkes HJ, Ruizendaal JJ et al. Exploring dendritic cell based vaccines targeting survivin for the treatment of head and neck cancer patients. J. Transl. Med. 11, 152-165 (2013). Survivin has been identified to be an inhibitor of apoptosis and is highly expressed in many cancers. A number o...

    journal_title:Immunotherapy

    pub_type: 评论,杂志文章

    doi:10.2217/imt.13.120

    authors: Lee WT

    更新日期:2013-11-01 00:00:00

  • A case of fulminant Type 1 diabetes following anti-PD1 immunotherapy in a genetically susceptible patient.

    abstract::Programmed cell death-1 protein (PD-1) is an immune checkpoint that has gained popularity in the treatment of several advanced cancers. Inhibiting this checkpoint is known to enhance immune response, but is also known to diminish immune tolerance and to increase autoimmune toxicity. We discuss a case of rapid onset fu...

    journal_title:Immunotherapy

    pub_type: 杂志文章

    doi:10.2217/imt-2017-0020

    authors: Araújo M,Ligeiro D,Costa L,Marques F,Trindade H,Correia JM,Fonseca C

    更新日期:2017-06-01 00:00:00

  • Immunomodulatory effects of Lactobacillus strains: emphasis on their effects on cancer cells.

    abstract::Lactobacilli are a group of normal microbiota whose immunomodulatory effects have been known for a long time. Recently, they have gained more attention for their direct and indirect effects on cancer cells. Several cell line experiments, animal model studies as well as clinical trials have indicated their inhibitory e...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt.15.92

    authors: Abedin-Do A,Taherian-Esfahani Z,Ghafouri-Fard S,Ghafouri-Fard S,Motevaseli E

    更新日期:2015-01-01 00:00:00

  • Pembrolizumab in a BRAF-mutant metastatic melanoma patient following a severe immune-related adverse event with ipilimumab.

    abstract::Currently, limited data exist on the safety of pembrolizumab in patients with metastatic melanoma who have developed severe immune-related adverse events following treatment with ipilimumab. We report a 45-year-old male patient with BRAF-mutant metastatic melanoma who discontinued treatment with ipilimumab due to trea...

    journal_title:Immunotherapy

    pub_type: 杂志文章

    doi:10.2217/imt-2015-0025

    authors: Aya F,Fernández-Martínez A,Gaba L,Victoria I,Tosca M,Carrera C,Prat A,Arance A

    更新日期:2016-06-01 00:00:00

  • Immunotherapy of chronic myeloid leukemia: present state and future prospects.

    abstract::In spite of the considerable successes that have been achieved in the treatment of chronic myeloid leukemia (CML), cure for the disease can only be obtained by the present means in a rather small minority of patients. During the past decade, considerable progress has been made in the understanding of the immunology of...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt.10.2

    authors: Vonka V

    更新日期:2010-03-01 00:00:00

  • Remarkable response to combined immunochemotherapy in patients with metastatic triple-negative breast cancer.

    abstract::Background: Progress in immunotherapy (IT) has shifted treatment paradigms for multiple malignancies. In March 2019, the combination of nab-paclitaxel and atezolizumab was approved by the US FDA for patients with PD-L1 positive metastatic triple-negative breast cancer based on positive results of the Impassion130 tria...

    journal_title:Immunotherapy

    pub_type: 杂志文章

    doi:10.2217/imt-2020-0202

    authors: Philipovskiy A,Chambers K,Konstantinidis I,McCallum R,Corral J,Gaur S

    更新日期:2020-12-01 00:00:00

  • First-line treatment of advanced/metastatic melanoma with anti-PD-1 antibodies: multicenter experience in Poland.

    abstract::Aim: To evaluate treatment results in advanced/metastatic melanoma patients treated with anti-PD-1 immunotherapy in routine practice in oncology centers in Poland. Methods: Multicenter retrospective analysis included 499 patients with unresectable/metastatic (stage IIIC-IV) melanoma treated with anti-PD-1 in first-lin...

    journal_title:Immunotherapy

    pub_type: 杂志文章

    doi:10.2217/imt-2020-0217

    authors: Cybulska-Stopa B,Pacholczak-Madej R,Kamińska-Winciorek G,Ziętek M,Czarnecka AM,Piejko K,Galus Ł,Ziółkowska B,Kieszko S,Kempa-Kamińska N,Calik J,Rolski J,Sałek-Zań A,Gajewska-Wicher K,Drosik-Kwaśniewska A,Rogala P,Kubiatow

    更新日期:2021-03-01 00:00:00

  • Consequences of B-cell-depleting therapy: hypogammaglobulinemia and impaired B-cell reconstitution.

    abstract::Rituximab is a chimeric monoclonal antibody used to treat hematologic and autoimmune diseases by depleting CD20-expressing B cells. Patients may develop hypogammaglobulinemia following treatment, with some demonstrating failure of B-cell recovery. The true frequency of hypogammaglobulinemia and/or impaired B-cell reco...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt-2017-0178

    authors: Sacco KA,Abraham RS

    更新日期:2018-06-01 00:00:00

  • Kinoids: a family of immunogens for active anticytokine immunotherapy applied to autoimmune diseases and cancer.

    abstract::The complex homeostasis of tissues is coordinated by the cytokine network and imbalances in this network may result in chronic immune disorders. Key specific cytokines, such as TNF-alpha, IFN-alpha, IL-4 or VEGF have been demonstrated to be overproduced or abnormally released in the microenvironment of pathologic tiss...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt.10.16

    authors: Bizzini B,Drouet B,Zagury D,Abitbol M,Burny A,Boissier MC

    更新日期:2010-05-01 00:00:00

  • Conference scene: progress with promising human antibodies.

    abstract::Antibodies and antibody-based therapeutics have become big business, with annual sales over US$50 billion, accounting for >6% of worldwide pharmaceutical revenues. Ten molecules have blockbuster status (>US$1 billion), with six generating more than US$6 billion in sales. In excess of 300 products based on this rapidly...

    journal_title:Immunotherapy

    pub_type: 杂志文章

    doi:10.2217/imt.12.5

    authors: Larrick JW

    更新日期:2012-03-01 00:00:00

  • Fibroblastic reticular cell infection by hemorrhagic fever viruses.

    abstract::Viral hemorrhagic fevers (VHFs) often cause high mortality with high infectivity, multiorgan failure, shock and hemorrhagic diathesis. Fibroblastic reticular cells (FRCs) within secondary lymphoid organs provide a supporting scaffold to T-lymphocyte areas. These cells regulate the movement of various immune cells and ...

    journal_title:Immunotherapy

    pub_type: 杂志文章

    doi:10.2217/1750743X.1.2.187

    authors: Steele KE,Anderson AO,Mohamadzadeh M

    更新日期:2009-03-01 00:00:00

  • Immunotherapy for pulmonary TB: antimicrobial peptides and their inducers.

    abstract::TB is an infectious disease that still has an enormous impact on public health worldwide. With the continuous increasing epidemic of multidrug-resistant TB, new drugs and vaccines are urgently needed. In the last decade there has been a broad advance in the knowledge of innate immunity in TB. Together with the growing...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt.13.111

    authors: Rivas-Santiago CE,Hernández-Pando R,Rivas-Santiago B

    更新日期:2013-10-01 00:00:00

  • Use of a multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) for bacterial meningitis prevention.

    abstract::Developing effective vaccines against Neisseria meningitidis serogroup B has been challenging for several reasons, including the fact that the capsular polysaccharide of N. meningitidis serogroup B is a poor antigen. Therefore, studies have focused on developing vaccines that target capsular protein meningococcal anti...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt.14.11

    authors: Esposito S,Castellazzi L,Bosco A,Musio A,Stoddard J

    更新日期:2014-01-01 00:00:00

  • Rare transformation to double hit lymphoma in Waldenstrom's macroglobulinemia.

    abstract::Waldenström macroglobulinemia (WM) is a lymphoproliferative lymphoma that is characterized by monoclonal immunoglobulin M (IgM) protein and bone marrow infiltration. Its incidence is rare and rarer still is its ability to transform to a B-cell lymphoma, particularly the aggressive diffuse large B-cell lymphoma, which ...

    journal_title:Immunotherapy

    pub_type: 杂志文章

    doi:10.2217/imt-2017-0027

    authors: Okolo ON,Johnson AC,Yun S,Arnold SJ,Anwer F

    更新日期:2017-08-01 00:00:00

  • Tumor-associated macrophages: implications in cancer immunotherapy.

    abstract::Tumor-associated macrophages (TAMs), representing most of the leukocyte population in solid tumors, demonstrate great phenotypic heterogeneity and diverse functional capabilities under the influence of the local tumor microenvironment. These anti-inflammatory and protumorigenic macrophages modulate the local microenvi...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt-2016-0135

    authors: Petty AJ,Yang Y

    更新日期:2017-03-01 00:00:00

  • Chimeric antigen receptor T cells immunotherapy: challenges and opportunities in hematological malignancies.

    abstract::Taking advantage of the cellular immune system is the mainstay of the adoptive cell therapy, to induce recognition and destruction of cancer cells. The impressive demonstration of this principle is chimeric antigen receptor-modified T (CAR-T)-cell therapy, which had a major impact on treating relapsed and refractory h...

    journal_title:Immunotherapy

    pub_type: 杂志文章

    doi:10.2217/imt-2020-0181

    authors: El-Khazragy N,Ghozy S,Emad P,Mourad M,Razza D,Farouk YK,Mohamed NA,Ahmed MK,Youssef T,Bahnasawy YM,Elmasery S

    更新日期:2020-12-01 00:00:00

  • Immunotherapeutic options for Epstein-Barr virus-associated lymphoproliferative disease following transplantation.

    abstract::Epstein-Barr virus-associated lymphoproliferative diseases (EBV-LPD) after hematopoietic stem cell transplantation or solid-organ transplantation remain a serious and potentially life-threatening complication. In the last decade, outcomes for EBV-LPD have significantly improved. Key to this success was the development...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt.10.43

    authors: Shaffer DR,Rooney CM,Gottschalk S

    更新日期:2010-09-01 00:00:00